Allarity Therapeutics
$1.13
59
+$0.04+3.67% Wednesday 20:00
Statistics
Day High
1.19
Day Low
1.1
52W High
2.35
52W Low
0.61
Volume
132,899
Avg. Volume
168,513
Mkt Cap
17.87M
P/E Ratio
0.25
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18MayExpected
Expected EPS
-0.22
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-50.31MNet Income
Analyst Ratings
$9.50Average Price Target
The highest estimate is 9.50.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALLR. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Merck
MRK
Mkt Cap214.76B
Pfizer
PFE
Mkt Cap140.15B
Novartis
NVS
Mkt Cap237.61B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Abbvie
ABBV
Mkt Cap385.18B
Astrazeneca
AZN
Mkt Cap256.58B
Roche
RHHBY
Mkt Cap258.9B
Lilly(Eli) &
LLY
Mkt Cap772.28B
About
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Thomas H. Jensen
Employees
6
Country
US
ISIN
US0167445008
Listings
0 Comments
Share your thoughts
FAQ
What is Allarity Therapeutics stock price today?▼
The current price of ALLR is $1.13 USD — it has increased by +3.67% in the past 24 hours. Watch Allarity Therapeutics stock price performance more closely on the chart.
What is Allarity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Allarity Therapeutics stocks are traded under the ticker ALLR.
Is Allarity Therapeutics stock price growing?▼
ALLR stock has risen by +5.61% compared to the previous week, the month change is a +13.57% rise, over the last year Allarity Therapeutics has showed a +27.89% increase.
What is Allarity Therapeutics market cap?▼
Today Allarity Therapeutics has the market capitalization of 17.87M
When is the next Allarity Therapeutics earnings date?▼
Allarity Therapeutics is going to release the next earnings report on May 18, 2026.
What were Allarity Therapeutics earnings last quarter?▼
ALLR earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.23 USD resulting in a +17.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Allarity Therapeutics revenue for the last year?▼
Allarity Therapeutics revenue for the last year amounts to 0 USD.
What is Allarity Therapeutics net income for the last year?▼
ALLR net income for the last year is -50.31M USD.
How many employees does Allarity Therapeutics have?▼
As of April 02, 2026, the company has 6 employees.
In which sector is Allarity Therapeutics located?▼
Allarity Therapeutics operates in the Health Care sector.
When did Allarity Therapeutics complete a stock split?▼
The last stock split for Allarity Therapeutics was on September 11, 2024 with a ratio of 1:30.
Where is Allarity Therapeutics headquartered?▼
Allarity Therapeutics is headquartered in Boston, US.